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Abstract:  
Background & Aims: Direct-acting antivirals (DAA) are effective in treatment of chronic 
hepatitis C virus (HCV) infection, although results for patients infected with genotype 3 are 
suboptimal. There are several regimens available but direct comparisons have not been 
made and are unlikely to occur. We aimed to identify the most effective DAA regimen for 
patients infected with HCV genotype 3 and to assess the role of ribavirin. 
 
Methods: We conducted a systematic search of Pubmed, Embase and Web of Science 
databases through March 2016. We performed a Bayesian network meta-analysis using a 
random effects model to indirectly compare regimens in patients with and without cirrhosis. 
We calculated mean estimated sustained virologic response (SVR) with 95% credible 
intervals (95% CrI) per regimen and effect of ribavirin as odds ratio. We focused on current 
recommended regimens and regimens under evaluation by regulatory authorities. 
 
Results: Our search identified 2167 articles; 27 studies (comprising 3415 patients) were 
included. Among patients without cirrhosis, the greatest rates of SVR were estimated for 
those receiving sofosbuvir + velpatasvir with ribavirin (99%; 95% CrI, 98%–100%) and 
without ribavirin (97%; 95% CrI, 95%–99%), sofosbuvir + daclatasvir + ribavirin (96%; 95% CrI, 
92%–98%), and sofosbuvir + peginterferon + ribavirin (95%; 95% CrI, 91%–98%), all for 12 
weeks. Among patients with cirrhosis, the highest rates of SVR were estimated for those 
receiving sofosbuvir + velpatasvir for 24 weeks (96%; 95% CrI, 92%–99%), sofosbuvir + 
daclatasvir + ribavirin for 24 weeks (94%; 95% CrI, 87%–98%), and sofosbuvir + velpatasvir + 
ribavirin for 12 weeks (94%; 95% CrI, 86%–98%). Ribavirin increases efficacy in patients with 
and without cirrhosis (odds ratio, 2.6–4.5). 
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Conclusion: An indirect comparison of DAA-based treatments, using Bayesian network meta-
analysis, found regimens containing sofosbuvir and velpatasvir to be the best option for 
patients with HCV genotype 3 infection. Our analyses indicate that ribavirin significantly 
increases rates of SVR and should be considered if tolerated.  
 
Keywords: Comparative Effectiveness; Mixed treatment comparison; NS5A inhibitor; NS5B 
inhibitor  
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Introduction 
Chronic hepatitis C infection (HCV) represents a chronic liver condition that may lead to end-
stage liver disease with cirrhosis and hepatocellular carcinoma.
1
 The advent of direct-acting 
antiviral drugs (DAA) has completely changed the outlook of HCV. Viral cure has become 
possible with treatments that last 12-24 weeks and are devoid of side effects. The efficacy of 
DAA based therapy depends on patient related factors such as liver cirrhosis but also on viral 
genotype. Randomized clinical trials (RCTs) indicate that current regimens result in sustained 
virological response (SVR) in > 90% of patients with genotype 1. 
2, 3
However, the evidence 
base for DAA therapies in genotype 3 is less extensive than for genotype 1. Also, treatment 
efficacy appears to be lower in genotype 3 patients, particularly in treatment experienced 
patients with cirrhosis.
6
  
The expansion of DAAs prompted the FDA in 2013 to allow single-arm trials that lack formal 
placebo arms but instead use historical controls as a comparator. 
7
 This has resulted in an 
uneven trial landscape with multiple trials focusing on individual regimens. Key agents used 
in HCV genotype 3 patients are sofosbuvir, combined with ribavirin, daclatasvir, or 
velpatasvir. The comparative efficacy of individual combinations is largely unknown, mainly 
because of the paucity of head-to-head trials, while that information is necessary to steer 
guideline development and clinical decision making.  
Our aim was to assess the comparative efficacy of all DAA regimens for HCV genotype 3 
using a network meta-analysis and to determine whether addition of ribavirin to DAA 
improves treatment efficacy.  
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Methods 
We conducted a systematic review and network meta-analysis according to an a priori 
written protocol. We used Preferred Reporting Items for Systematic Reviews and Network 
meta-analysis (PRISMA NMA) guidelines for this purpose.
9
 
 
Systematic review 
We performed a systematic search to identify studies in HCV genotype 3 patients treated 
with DAAs. Together with a medical librarian we designed the search strategy for the 
Pubmed, Embase and Web of Science databases, and conducted the final search on 15 
March 2016 (Supplementary file 1). To include all available data we performed a manual 
search of abstract books of the European Association for the Study of the Liver (EASL) and 
the American Association for the Study Liver Diseases (AASLD) conferences in 2015. Two 
researchers (BA and FB) independently screened articles following a dual pronged approach: 
screening on title and abstract and full text screening. Disagreements were resolved by a 
third researcher (WK). We included studies (1) with patients above 18 years with HCV 
genotype 3, (2) RCTs, prospective clinical trials and/or real life studies with at least one DAA. 
We excluded studies (1) without results specified for HCV genotype 3, (2) where no 
sustained virological response (SVR) was reported, or (3) studies involving acute hepatitis C 
infected patients.  
 
Outcomes, data extraction and risk of bias assessment 
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The primary outcome was the mean estimated probability of SVR per studied regimen. SVR 
was defined as an undetectable HCV RNA 12 weeks after cessation of treatment. One author 
(BA) extracted study characteristics and intention-to-treat SVR data per regimen and entered 
this in a structured electronic database (Castoredc ©). A second researcher crosschecked all 
entered data (FB). Two authors (FB, BA) independently assessed the quality of studies using 
the Cochrane Collaboration risk of bias tool.
10
 Disagreements were resolved by a third 
researcher (WK). 
 
Statistical analysis 
We conducted the network meta-analysis using Bayesian Markov Chain Monte Carlo 
(MCMC) methods. We used a random effects model with non-informative priors comparable 
to the network meta-analysis model of treatment response (NMA-TR) of Goring.
11
 Direct and 
indirect evidence for all studied regimens were combined to estimate the probability of SVR 
per studied regimen, with a 95% equal tail Credible Interval (95%CrI), by means of a logistic 
regression model. We included the following fixed factors in the model: type of DAAs, 
ribavirin (binary), duration of therapy (12 or 16 or 24 weeks), presence of cirrhosis as 
prognostic factor for efficacy, and interaction of ribavirin and cirrhosis. As random effect we 
added the study, in order to model the positive correlation between study arms from the 
same study and to reflect deviations from the mean effects due to specific study and patient 
characteristics. The additional effect of ribavirin was estimated by means of an odds ratio 
(OR). The MCMC approach was based on 3 chains and updated with 200,000 simulations, 
thinning 1 per 10 and a burn-in of 10,000. We checked that the MCMC procedures had 
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reached convergence by visually inspecting the history trace plots and the autocorrelation 
plots for irregularities. 
To identify the most effective regimen, we focused on a subset of regimens recommended in 
guidelines, authorized in the market or under evaluation by regulatory authorities.
12-14
 We 
ranked these regimens according to estimated SVR rates.
15
 Further, we performed 
conventional meta-analyses per regimen to assess inconsistency and fit of the model. 
Heterogeneity was assessed by the estimated between-study variation τ
2
 of the network 
meta-analysis and by I
2
 of the meta-analyses per regimen.  
 
Sensitivity analyses 
We performed four sensitivity analyses to assess the reliability and robustness of the model 
and to increase homogeneity of the population: (a) we included studies with a low risk of 
bias and studies with only a high risk of bias on blinding of participants as SVR is an objective 
outcome measure, (b) we included only regimens available in the market or under 
evaluation by regulatory authorities, (c) we excluded studies with patients with 
decompensated cirrhosis, and (d) we excluded studies with HIV/HCV co-infected patients. 
Because the effect of ribavirin is expected to be lower when added to a regimen consisting 
of 2 DAAs we did an additional analysis to assess the effect of ribavirin when combined with 
2 DAAs. Treatment status (naive or experienced) was not included in the model because of 
limited available data specified on both cirrhosis status and treatment status per patient. To 
explore the effect of this choice, we performed an analysis with treatment status instead of 
cirrhosis in the model. All analyses were performed in WinBUGS 1.4.3 and R version 3.0.1 
(R2winbugs). 
16, 17
 The WinBUGS syntax is available in supplementary file 2. 
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Results 
Treatment landscape 
Of the 2167 identified articles, we selected 26 papers (21 full text, 5 abstracts) describing 27 
studies (16 RCTs, 6 single arm studies, and 5 observational cohorts, Figure 1).
18-43
 Overall, the 
27 studies included 3415 patients, consisting of 2294 (67%) treatment naïve patients and 
1088 (32%) patients with cirrhosis. Eleven combinations of DAAs were studied, duration of 
therapy varied between 8 to 24 weeks with or without addition of ribavirin (Table 1 and 
supplementary file 3). We excluded the 8 weeks regimens from our NMA, because only few 
patients were treated with 8 weeks regimens (n=13). There was variation in the number of 
patients studied per regimen, range 7-868). We designed three networks to connect 
regimens, but the majority of regimens were connected in network 1 and 2 (Figure 2).  
 
Sustained virological response in non-cirrhotic patients 
Twenty-two different regimens were studied in non-cirrhotic HCV genotype 3 patients 
(Figure 3a). Highest SVR rates were estimated for sofosbuvir + daclatasvir + ribavirin for 24 
weeks (98.9%, 95%CrI 97.6-99.6), sofosbuvir + velpatasvir + ribavirin for 12 weeks (98.8%, 
95%CrI 97.5-99.6) and sofosbuvir + daclatasvir + ribavirin for 16 weeks (98.0%, 95%CrI 95.7-
99.2).  
We ranked a subset of the regimens (the clinically relevant regimens as based on guidelines 
and clinical practice, shown in supplementary file 4 and marked grey in Figure 2) from 1 to 6. 
In this subset, the regimen sofosbuvir + velpatasvir + ribavirin for 12 weeks had highest 
probability to be ranked first, sofosbuvir + velpatasvir for 12 weeks to be ranked second, and 
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sofosbuvir + daclatasvir + ribavirin for 12 weeks to be ranked third etcetera (supplementary 
file 4a). Based on the ranking we estimated the differences in SVR rates between treatments 
(Table 2). Sofosbuvir + velpatasvir + ribavirin for 12 weeks reached higher SVR rates than all 
other recommended regimens in the subset (range 2-12% higher SVR). In contrast, 
sofosbuvir + velpatasvir for 12 weeks, sofosbuvir + daclatasvir + ribavirin for 12 weeks and 
sofosbuvir + peginterferon + ribavirin for 12 weeks had similar SVR rates. Sofosbuvir + 
ribavirin for 24 weeks had a similar estimated SVR to sofosbuvir + daclatasvir for 12 weeks; 
both were inferior to other reported regimens. 
 
Sustained virological response in cirrhotic patients 
In total, 19 different regimens were studied in cirrhotic HCV genotype 3 patients. Highest 
SVR rates were estimated for: sofosbuvir + velpatasvir for 24 weeks (96.3%, 95%CrI 92.0-
98.7), sofosbuvir + daclatasvir + ribavirin for 24 weeks (94.1%, 95%CrI 86.8-98.1) and 
sofosbuvir + velpatasvir + ribavirin for 12 weeks (93.7%, 95%CrI 85.9-98.0) (Figure 3b). 
Ranking and comparison of the subset of clinically important regimens resulted in sofosbuvir 
+ velpatasvir for 24 weeks to be ranked first, sofosbuvir + daclatasvir + ribavirin for 24 weeks 
to be ranked second and sofosbuvir + velpatasvir + ribavirin for 12 weeks to be ranked third, 
etcetera (supplementary file 4b). However when we compared the regimens in the subset to 
each other, similar SVR rates were estimated for the first three ranked regimens (Table 3). 
sofosbuvir + velpatasvir for 12 weeks resulted in 7% lower SVR, while sofosbuvir + 
peginterferon + ribavirin for 12 weeks resulted in 16% lower SVR than sofosbuvir + 
velpatasvir + ribavirin for 12 weeks. Sofosbuvir + ribavirin for 24 weeks was inferior to all 
other regimens, with 22-40% lower SVR estimates.  
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Effect of ribavirin  
In patients without cirrhosis the OR of ribavirin was 2.6 (95%CrI 1.3-4.7), and in patients with 
cirrhosis 4.5 (95%CrI 2.5-7.7). We also performed an analysis with only studies including 2 
DAAs +/- ribavirin. We found an OR of 6.5 (95%CrI 1.9-17.8) in patients without cirrhosis and 
OR 3.9 (95%CrI 2.0-7.0) in patients with cirrhosis. Ribavirin had a significant additional effect, 
even when used with 2 DAAs in both cirrhotic and non-cirrhotic patients.  
 
Fit of the model and sensitivity analyses 
To assess the consistency and fit of the model we performed direct meta-analyses of 
regimens and the results were largely similar to our network meta-analysis, with the 
exception of two regimens: sofosbuvir for 12 weeks and sofosbuvir + velpatasvir for 24 
weeks. These 2 regimens were only studied once in 7 and 12 patients respectively.
18, 26
 With 
regard to heterogeneity, the majority of meta-analyses per regimen had an I
2 
<50%, except 
for 3 regimens (sofosbuvir + ribavirin 12 weeks, sofosbuvir + ribavirin 16 weeks (patients 
without cirrhosis), and sofosbuvir + velpatasvir(100mg) 12 weeks (patients with 
cirrhosis))(Supplementary file 5). The network meta-analysis resulted in an overall estimated 
τ
2
 of 0.78 (95%CrI 0.27-1.73), suggesting between-study variation in the SVR rates. We 
performed four sensitivity analyses (Supplementary file 6). For the first sensitivity analysis 
we excluded studies with a high risk of bias, except studies with only a high risk of bias on 
blinding of participants (Supplementary file 7). Overall estimated SVR rates were lower and 
95%CrI wider; SVR for sofosbuvir+ daclatasvir regimens dropped while sofosbuvir + 
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velpatasvir regimens had similar SVR estimates as in the primary analysis. Results were 
consistent with the primary analysis in the other three sensitivity analyses. We also built a 
model where cirrhosis was replaced by treatment status (treatment naive vs. treatment 
experienced). Again, estimated SVR and ranking were largely similar to the overall results 
(Supplementary file 8). 
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Discussion 
In this systematic review and network meta-analysis, we combined data from 27 studies to 
establish a hierarchy of available treatment regimens for HCV genotype 3.  The key finding is 
that sofosbuvir-velpatasvir regimens achieve the highest efficacy in HCV genotype 3: 
sofosbuvir + velpatasvir + ribavirin for 12 weeks in non-cirrhotics and sofosbuvir + velpatasvir 
(without ribavirin) for 24 weeks or with ribavirin for 12 weeks in cirrhotics, although similar 
estimated SVR rates can be reached with sofosbuvir + daclatasvir + ribavirin for 24 weeks. In 
patients without cirrhosis, regimens such as sofosbuvir + peginterferon + ribavirin and 
sofosbuvir + daclatasvir+ ribavirin for 12 weeks only had 1-4% lower estimated SVR rates, 
and remain an option for treatment. The advantage of sofosbuvir + velpatasvir over other 
regimens is that ribavirin can be omitted in non-cirrhotics and that it shortens duration of 
treatment in cirrhotics.  
Second, we established the added value of ribavirin (OR 2.6-4.5), regardless of the presence 
of cirrhosis. However, it is important to keep in mind that the actual effect of adding 
ribavirin on SVR rates depends on the efficacy of the backbone regimen: the increase in SVR 
due to ribavirin is highest with regimens that have a lower intrinsic efficacy. A recent review 
and current AASLD guidelines suggest that ribavirin can be dropped from the combination 
sofosbuvir + daclatasvir in non-cirrhotic genotype 3 patients. Our data suggest that in this 
case SVR drops by 6%. In clinical practice, the effect of ribavirin has to be traded off against 
both the side effect profile of ribavirin and the expected reduction in costs related to the 
DAA. The authors of this review and guideline recommend use of ribavirin in cirrhosis which 
is supported by our data.
12, 45
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A third finding is the identification of regimens that are clearly inferior in HCV genotype 3: 
sofosbuvir + daclatasvir for 12 weeks and sofosbuvir + ribavirin for 24 weeks in non-
cirrhotics. Both achieved 5-12% lower SVR rates compared to other recommended regimens. 
In cirrhotics, differences in efficacy were more visible: sofosbuvir + ribavirin for 24 weeks 
was obviously inferior to other reported regimens (22-40% lower SVR rates) and should be 
considered obsolete.   
 
The lack of head-to-head trials is an important issue for guideline developers and physicians, 
and drives researchers to perform network meta-analyses. 
44
 In the field of hepatitis C, some 
network meta-analyses have been performed to assess relative efficacy of DAAs in HCV 
genotype 1. 
3, 47, 48
 Because genotype is an important predictor for response, these results 
cannot be compared with genotype 3. The technique of network meta-analysis is not only of 
value in HCV, but has merits for other disease entities such as alcoholic hepatitis or Crohn’s 
disease. 
49-51
 Results of network meta-analyses support physicians and guideline developers 
in decision making, but can also identify treatments which should be compared head-to-
head, in our study this could be the first until fourth ranked regimes. 
Our study comes with strengths and limitations. We combined all available evidence of DAA-
regimens for HCV genotype 3 with use of Bayesian statistics. Current guidelines do not rank 
therapies as formal head to head trials are lacking. Our method enables identification of a 
hierarchy of therapies for HCV genotype 3. One of the limitations of our study is that results 
are based on extensive networks with in a few cases only one or no study per connection. 
This forced us to perform an arm-based rather than a comparison-based network meta-
analysis. This approach is supported by the literature for HCV, but does impede 
inconsistency assessment. 
11
 However, our model produced similar outcomes as the 
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conventional meta-analyses per regimen, which bolsters our conclusions. Further, estimated 
SVR rates of peginterferon and ribavirin therapy in our study do reflect SVR rates in the 
literature.
52
 Another limitation of our network meta-analysis is the risk of conceptual 
heterogeneity, reflecting differences between trials which may impair comparability. We 
used several strategies to target heterogeneity: 1) we used a random effects model (by 
including a study effect in our model), 2) we have split the analyses for patients with and 
without cirrhosis, and 3) we performed sensitivity analyses to increase homogeneity, which 
showed similar results. Moreover SVR is an objective outcome which decreases the risk of 
heterogeneity.
8
 Many studies in our network analysis have a high risk of bias. Exclusion of 
these studies in our sensitivity analysis resulted in a similar ranking of regimens, but 
estimated SVR rates were lower and 95%CrIs were wider. In real world, SVR rates might be 
compromised in view of the lower generalizability of trials, but we do not expect that the 
hierarchy is affected. Lastly, we were not able to assess publication bias formally, as the 
studies per regimen ranged from 1-7, nevertheless we do not expect publication bias as the 
field of HCV evolves rapidly and trial results are needed for evaluation by regulatory 
authorities. 
10
 
Implications for clinical practice 
The findings of our network meta-analysis can be used to prioritize DAA regimens for HCV 
genotype 3 patients in guidelines and clinical practice. In patients without cirrhosis we 
focused on 12 week regimens and four regimens have an estimated SVR rate of 95% or 
higher: sofosbuvir + velpatasvir + ribavirin for 12 weeks is the best option, directly followed 
by sofosbuvir + velpatasvir, sofosbuvir + daclatasvir + ribavirin and sofosbuvir + 
peginterferon + ribavirin for 12 weeks. Sofosbuvir + ribavirin for 24 weeks and sofosbuvir + 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
daclatasvir for 12 weeks are inferior. In patients with cirrhosis sofosbuvir + velpatasvir with 
ribavirin for 12 weeks or without ribavirin for 24 weeks and sofosbuvir + daclatasvir + 
ribavirin for 24 weeks can be recommended. Sofosbuvir + velpatasvir for 12 weeks had 7-
10% lower estimated SVR rates compared to other regimes so can be considered as 
alternative instead of recommended regimen in cirrhotic patients. 
12
 Sofosbuvir + ribavirin 
for 24 weeks is inferior to newer regimens. Our study also shows that ribavirin significantly 
increases the estimated SVR rates, however the precise effect is dependent on the actual 
DAA combination. In clinical practice, choice of treatment may depend on several factors, 
such as availability and price of DAAs, tolerance of ribavirin, risk of adverse events or drug-
drug interactions, and presence of resistance associated substitutions.  
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Tables and figures 
Table 1. Baseline characteristics of included studies 
Author Acronym /  
NCT number 
Year Location Population and design Intervention Duration 
in weeks 
N Cirrhosis 
- n (%) 
SVR - 
n (%)
* 
Foster 
22
 NCT00561015 2011 EU Phase IIa RCT, TN G2-3 pts TPR + PR vs. PR 24 26 1 (4) 14( 54) 
Lawitz 
29
 FISSION 2013 NA, EU, ANZ Phase III RCT, TN G2-3 pts SOF + RBV vs. PR 12-24 359 NR 212 (59) 
Jacobson 
28
  
POSITRON 2013 NA, ANZ Phase III RCT, TN G2-3 pts in which interferon 
was not an option 
SOF + RBV vs. Placebo 12 135  14 (10) 60 (61) 
Jacobson 
28
 
FUSION 2013 NA, ANZ Phase III RCT, TE G2-3 pts SOF + RBV 12-16 127 49 (39) 58 (46) 
Gane 
26
 ELECTRON 2013 ANZ Phase IIa RCT, TN G2-3 pts SOF ± RBV / PR 12∫ 42 0 40 (95) 
Zeuzem 
43
 VALENCE 2014 EU Phase III RCT, later unblinded during study, TN 
and TE G2-3 pts 
SOF + RBV vs. Placebo 12-24 328 62 (19) 216 (83) 
Sulkowski 
40
 
PHOTON-1 2014 NA Phase III single arm study with TN and TE 
HCV/HIV coinfected G1-3 pts 
SOF + RBV  12-24 59 12 (20) 44 (75) 
Sulkowski 
39
 
AI444040 2014 NA RCT, TN G1-3 pts SOF + DCV ± RBV 24 18 0 16 (89) 
Foster 
21
 ASTRAL-3 2015 NA, EU, ANZ Phase III RCT, TN and TE G3 pts SOF + VEL vs. SOF + 
RBV 
12 552 163 (30) 485 (88) 
Foster 
24
 BOSON 2015 NA, EU, ANZ Phase III RCT, TN and TE G3 pts SOF + RBV / PR 12-24 544 171 (31) 449 (83) 
Pianko 
36
 NCT01909804 2015 NA, ANZ Phase II RCT, TE G1 and 3 pts SOF + VEL(25mg and 
100 mg) ± RBV 
12 210 103 (49) 186 (89) 
Nelson 
35
 ALLY-3 2015 NA Phase III single arm study, TN and TE G3 pts SOF + DCV 12 152 32 (21) 135 (89) 
Molina 
34
 PHOTON-2 2015 EU, ANZ Phase III single arm study, TN and TE HCV/HIV co-
infected G1-4 pts 
SOF + RBV 24 106 26 (25) 94 (89) 
Gane 
25
 NCT01826981 2015 ANZ Phase II RCT (TN) and single arm (TE) study in pts 
with G3 or G6 
SOF + LDV ± RBV 12 101 32 (32) 83 (82) 
Dore 
19
 AI444031 2015 NA, EU, ANZ Phase IIb RCT, TN G2-3 pts DCV + PR vs. PR 12-24 80 18 (23) 53 (66) 
Everson 
20
 NCT01858766 2015 NA Phase II RCT, TN G1-6 pts SOF + VEL (25mg and 
100mg) 
12 54 0 50 (93) 
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Curry 
18
 ASTRAL-4 2015 NA Phase III RCT, TN and TE G1-6 pts with 
decompensated cirrhosis 
SOF + VEL ± RBV 12-24 39 39 (100)  24 (62) 
Lawitz 
30
 NR 2015 NA Phase II single arm study, TE G2-3 pts SOF + PR 12 24 12 (50) 20 (83) 
Lawitz 
31
 NCT01458535 2015 NA Phase II trial with sequential enrollment, TN G1-3 
pts 
OMB + ABT-450/r ± 
RBV 
12 21 0 6 (29) 
Lin 
33
 NR 2015 NR Single arm study, G2-3 pts, decompensated 
cirrhosis was included 
SOF + RBV  24 8 NR 6 (75) 
Welzel 
41
 CUP 2015 EU Observational cohort (compassionate use 
program), G3 pts both HCV and HCV/HIV 
coinfected, decompensated cirrhosis was 
included 
SOF + DCV ± RBV 12-24 24 22 (92)  22 (92) 
Hezode 
27
 ATU 2015 EU (France) Observational cohort (compassionate use 
program), TN and TE G3 pts both HCV and 
HCV/HIV coinfected, decompensated cirrhosis 
was included 
SOF + DCV ± RBV 12-24 78 NR† 70 (90) 
Poordad 
37
 ALLY-1 2015 NA Single arm study, TN and TE G1-6 pts with 
advanced fibrosis or post-liver transplant HCV 
recurrence 
SOF + DCV + RBV 12 17 17 (100)  15 (88) 
Wyles 
42
 ALLY-2 2015 NA Phase II RCT (TN) and single arm (TE), G1-4 
HCV/HIV coinfected pts 
SOF + DCV 12 ∫ 13 2 (15) 12 (92) 
Foster 
23
 EAP 2016 EU Observational cohort (expanded access 
programme), G1-6 TN and TE, both HCV and 
HCV/HIV coinfected pts, decompensated 
cirrhosis was included 
SOF + LDV ± RBV vs. 
SOF + DCV ± RBV 
12 192 172 (90) 132 (69) 
Shah 
38
 NR 2016 Asia (India) RCT, TN G1 and G3 pts SOF + RBV 16-24 59 14 (24) 57 (97) 
Leroy 
32
 ALLY-3+ 2016 EU, ANZ Phase IIIb RCT, TN and TE G3 pts SOF + DCV + RBV 12-16 50 36 (72) 45 (90) 
NR = Not Reported, EU = Europe, NA= North America, ANZ = Australia and New-Zealand, TN = treatment naive, TE = treatment experienced, HCV= hepatitis C virus, HIV = 
human immunodeficiency virus, RCT = randomized clinical trial, pts = patients, G = genotype. 
Interventions: TPR = telaprevir, RBV = ribavirin, PR = peginterferon and RBV, SOF = sofosbuvir, DCV = daclatasvir, VEL = velpatasvir (100 mg unless otherwise indicated), LDV 
= ledipasvir, OMB = ombitasvir, ABT-450/r = paritaprevir/ritonavir. 
* in case of placebo, these patients are excluded from SVR calculations  
∫ The treatment arms with 8 weeks duraXon are excluded from the analysis 
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Table 2. Mean difference in estimated SVR rate (%) between regimens in non-cirrhotic HCV genotype 3 patients (95%CrI) 
Regimen 
SVR (95%CrI) 
SOF+VEL+RBV 12  
98.8 (97.5-99.6) 
SOF+VEL 12  
97.2 (94.7-98.8) 
SOF+DCV+RBV 12 
95.6 (91.6-98.1) 
SOF+PR 12  
95.0 (90.6-97.8) 
SOF+DCV 12  
89.9 (80.9-95.6) 
SOF+RBV 24  
87.3 (80.5-92.4) 
1. SOF+VEL+RBV 12  
98.8 (97.5-99.6) 
     1.6 (0.4-3.5)*   3.2 (0.7-7.1)*   3.8 (1.1 – 8.1)*    8.9 (3.0 – 18.2)*   11.6 (6.8 – 18.0)* 
2. SOF+VEL 12  
97.2 (94.7-98.8) 
  
  1.5 (- 2.0 – 6.0)   2.2 (- 0.9 – 6.4)   7.3 (1.5 – 16.3)*   10.0 (5.5 – 16.0)* 
3. SOF+DCV+RBV 12 
95.6 (91.6-98.1) 
  
   0.6 (- 4.3 – 5.8)   5.7 (1.3 – 12.7)*   8.4 (2.0 – 15.7)* 
4. SOF+PR12  
95.0 (90.6-97.8) 
  
     5.1 (- 2.1 – 14.7)   7.7 (3.3 – 13.2)* 
5. SOF+DCV 12  
89.9 (80.9-95.6) 
  
 
 
    2.7 (- 8.0 – 11.8) 
6. SOF+RBV 24  
87.3 (80.5-92.4) 
  
 
   
Subset of regimens are ordered based on ranking statistics (supplementary file 4). Mean differences between 2 regimens are presented (with 95%credibility interval). * and 
bold indicates a significantly higher estimated SVR rate. Abbreviations: SOF = sofosbuvir, VEL = velpatasvir 100 mg, RBV = ribavirin, PR = peginterferon and RBV, DCV = 
daclatasvir, 12 = 12 weeks, 24 = 24 weeks.  
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Table 3. Mean difference in estimated SVR rate (%) between regimens in cirrhotic HCV genotype 3 patients (95%CrI) 
Regimen 
SVR (95%CrI) 
SOF+VEL 24 
96.3 (92.0-98.7) 
SOF+DCV+RBV 24 
94.1 (86.8-98.1) 
SOF+VEL+RBV 12 
93.7 (85.9-98.0) 
SOF+DCV 24 
87.3 (75.8-94.7) 
SOF+VEL 12 
86.8 (77.4-93.6) 
SOF+DCV+RBV 12 
80.1 (62.7-92.0) 
SOF+PR 12 
77.8 (59.6-90.5) 
SOF+RBV 24 
56.3 (37.6-73.8) 
1. SOF+VEL 24 
96.3 (92.0-98.7) 
 2.2 (- 2.5 – 8.9)  2.6 (- 0.9 – 8.5) 9.0 (2.0 – 19.9)* 9.5 (4.8 – 15.8)* 16.2 (4.0 – 33.7)* 18.5 (6.4 – 35.7)* 40.0 (24.2 – 57.0)* 
2. SOF+DCV+RBV 24 
94.1 (86.8-98.1) 
 
 
0.4 (- 5.9 – 6.8) 6.9 (1.9 – 14.4)* 7.3 (- 1.2 – 16.7) 14.0 (5.7 – 25.7)* 16.3 (4.0 – 33.1)* 37.9 (22.2 – 54.3)* 
3. SOF+VEL+RBV 12 
93.7 (85.9-98.0) 
   
 
6.5 (- 3.8 – 18.9) 7.0 (2.4 – 12.8)* 13.6 (3.0 – 29.1)* 15.9 (4.6 – 31.9)* 37.4 (22.9 – 53.1)* 
4. SOF+DCV 24 
87.3 (75.8-94.7) 
 
   
0.5 (- 12.7 – 11.5) 7.2 (- 2.8 – 20.5) 9.4 (- 6.2 – 27.8) 31.0 (13.3 – 49.1)* 
5. SOF+VEL 12 
86.8 (77.4-93.6) 
 
    
6.7 (- 7.2 – 24.3) 9.0 (- 3.4 – 25.4) 30.5 (16.4 – 46.3)* 
6. SOF+DCV+RBV 12 
80.1 (62.7-92.0) 
 
    
 2.3 (- 15.3 – 20.3) 23.8 (5.8 – 42.1)* 
7. SOF+PR 12 
77.8 (59.6-90.5) 
 
    
 
 
21.6 (9.3 – 34.5)* 
8. SOF+RBV 24 
56.3 (37.6-73.8) 
 
    
 
  
Subset of regimens are ordered based on ranking statistics (supplementary file 4). Mean differences between 2 regimens are presented (with 95%credibility interval). * and 
bold indicates a significantly higher estimated SVR rate. Abbreviations: SOF = sofosbuvir, VEL = velpatasvir 100mg, RBV = ribavirin, PR = peginterferon and RBV, DCV = 
daclatasvir, 12 = 12 weeks, 24 = 24 weeks. 
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Figure 1. Study selection flowchart 
Legend Figure 1. Study selection flowchart summarizing selection and identification of trials and studies. GT3 = 
genotype 3, SVR12/24= sustained virological response at 12 or 24 weeks after cessation of treatment, DAA = 
direct acting antiviral. 
 
Figure 2. Networks of studies 
Legend Figure 2. Evidence network of all DAA-based regimens studied in chronic hepatitis C genotype 3 
patients. Thickness of the lines represent number of studies (connecting lines) or total number of patients 
studied (box lines). Within the box the DAA combination with duration (12, 16 or 24 weeks) is visible. Grey 
marked regimes are selected for ranking. Abbreviations: SOF = sofosbuvir, VEL = velpatasvir 100 mg, VEL(25) = 
velpatasvir 25 mg, RBV = ribavirin, PR = peginterferon and RBV, DCV = daclatasvir, LDV = ledipasvir, TPR = 
telaprevir, OBV = ombitasvir, PTV = paritaprevir/ritonavir, 12 = 12 weeks, 16 = 16 weeks, 24 = 24 weeks. 
 
Figure 3a. Estimated SVR rates per regimen for non-cirrhotic patients 
Legend Figure 3a. The figure shows the mean estimated probability on Sustained Virological Response (SVR) 
per regimen with 95%CrI. The SVR rates are estimated for patients without cirrhosis. Abbreviations: SOF = 
sofosbuvir, VEL = velpatasvir, RBV = ribavirin, PR = peginterferon and RBV, DCV = daclatasvir, LDV = ledipasvir, 
TPR = telaprevir, OBV = ombitasvir, PTV = paritaprevir/ritonavir, 12 = 12 weeks, 16 = 16 weeks, 24 = 24 weeks. 
 
Figure 3b. Estimated SVR rates per regimen for cirrhotic patients 
Legend Figure 3b. The figure shows the mean estimated probability on Sustained Virological Response (SVR) 
per regimen with 95%CrI. The SVR rates are estimated for patients with cirrhosis. Abbreviations: SOF = 
sofosbuvir, VEL = velpatasvir, RBV = ribavirin, PR = peginterferon and RBV, DCV = daclatasvir, LDV = ledipasvir, 
12 = 12 weeks, 16 = 16 weeks, 24 = 24 weeks. 
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PRISMA NMA Checklist of Items to Include When Reporting A Systematic Review 
Involving a Network Meta-analysis 
 
 
Section/Topic Item 
# 
Checklist Item Reported 
on Page # 
TITLE    
Title 1 Identify the report as a systematic review incorporating a 
network meta-analysis (or related form of meta-analysis).  
p1 
 
  
 
ABSTRACT    
Structured 
summary  
2 Provide a structured summary including, as applicable:  
Background: main objectives 
Methods: data sources; study eligibility criteria, 
participants, and interventions; study appraisal; and 
synthesis methods, such as network meta-analysis.  
Results: number of studies and participants identified; 
summary estimates with corresponding 
confidence/credible intervals; treatment rankings may 
also be discussed. Authors may choose to summarize 
pairwise comparisons against a chosen treatment 
included in their analyses for brevity. 
Discussion/Conclusions: limitations; conclusions and 
implications of findings. 
Other: primary source of funding; systematic review 
registration number with registry name. 
p4 
 
   
INTRODUCTION    
Rationale  3 Describe the rationale for the review in the context of what 
is already known, including mention of why a network 
meta-analysis has been conducted.  
p6-7 
Objectives  4 Provide an explicit statement of questions being addressed, 
with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
p7 
    
METHODS    
Protocol and 
registration  
5 Indicate whether a review protocol exists and if and where 
it can be accessed (e.g., Web address); and, if available, 
provide registration information, including registration 
number.  
p8 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of 
follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria 
for eligibility, giving rationale. Clearly describe eligible 
treatments included in the treatment network, and note 
whether any have been clustered or merged into the same 
node (with justification).  
p8 
Information 
sources  
7 Describe all information sources (e.g., databases with dates 
of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
p8 
Search  8 Present full electronic search strategy for at least one p8 and 
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database, including any limits used, such that it could be 
repeated.  
Supp file 1 
Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
p8 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., 
piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from 
investigators.  
p9 
Data items  11 List and define all variables for which data were sought 
(e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
p9 
Geometry of the 
network 
S1 Describe methods used to explore the geometry of the 
treatment network under study and potential biases related 
to it. This should include how the evidence base has been 
graphically summarized for presentation, and what 
characteristics were compiled and used to describe the 
evidence base to readers. 
p9-10 
Risk of bias within 
individual studies  
12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether this 
was done at the study or outcome level), and how this 
information is to be used in any data synthesis.  
p9-10 
Summary measures  13 State the principal summary measures (e.g., risk ratio, 
difference in means). Also describe the use of additional 
summary measures assessed, such as treatment rankings 
and surface under the cumulative ranking curve (SUCRA) 
values, as well as modified approaches used to present 
summary findings from meta-analyses. 
p9-10 
Planned methods of 
analysis 
14 Describe the methods of handling data and combining 
results of studies for each network meta-analysis. This 
should include, but not be limited to:   
• Handling of multi-arm trials; 
• Selection of variance structure; 
• Selection of prior distributions in Bayesian 
analyses; and 
•  Assessment of model fit.  
p9-10 
Assessment of 
Inconsistency 
S2 Describe the statistical methods used to evaluate the 
agreement of direct and indirect evidence in the treatment 
network(s) studied. Describe efforts taken to address its 
presence when found. 
p10 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
p9-10 
Additional analyses  16 Describe methods of additional analyses if done, indicating 
which were pre-specified. This may include, but not be 
limited to, the following:  
• Sensitivity or subgroup analyses; 
• Meta-regression analyses;  
• Alternative formulations of the treatment network; 
and 
• Use of alternative prior distributions for Bayesian 
analyses (if applicable).  
p10 
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RESULTS†    
Study selection  17 Give numbers of studies screened, assessed for eligibility, 
and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
p11 and fig 
1 
Presentation of 
network structure 
S3 Provide a network graph of the included studies to enable 
visualization of the geometry of the treatment network.  
p11 and fig 
2 
Summary of 
network geometry 
S4 Provide a brief overview of characteristics of the treatment 
network. This may include commentary on the abundance 
of trials and randomized patients for the different 
interventions and pairwise comparisons in the network, 
gaps of evidence in the treatment network, and potential 
biases reflected by the network structure. 
p11 and 
table 1 
Study 
characteristics  
18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
p11 and 
table 1 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, 
any outcome level assessment.  
p13 and 
Suppl file 7 
Results of 
individual studies  
20 For all outcomes considered (benefits or harms), present, 
for each study: 1) simple summary data for each 
intervention group, and 2) effect estimates and confidence 
intervals. Modified approaches may be needed to deal with 
information from larger networks. 
p11 and p13 
and Suppl 
file 3 and 5 
Synthesis of results  21 Present results of each meta-analysis done, including 
confidence/credible intervals. In larger networks, authors 
may focus on comparisons versus a particular comparator 
(e.g. placebo or standard care), with full findings presented 
in an appendix. League tables and forest plots may be 
considered to summarize pairwise comparisons. If 
additional summary measures were explored (such as 
treatment rankings), these should also be presented. 
p11-12, fig 
3a and 3b, 
suppl file 6 
Exploration for 
inconsistency 
S5 Describe results from investigations of inconsistency. This 
may include such information as measures of model fit to 
compare consistency and inconsistency models, P values 
from statistical tests, or summary of inconsistency 
estimates from different parts of the treatment network. 
p13-14 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across 
studies for the evidence base being studied.  
p13 and 
suppl file 7  
Results of 
additional analyses 
23 Give results of additional analyses, if done (e.g., sensitivity 
or subgroup analyses, meta-regression analyses, alternative 
network geometries studied, alternative choice of prior 
distributions for Bayesian analyses, and so forth).  
p13-14 and 
suppl file 6 
   
 
DISCUSSION    
Summary of 
evidence  
24 Summarize the main findings, including the strength of 
evidence for each main outcome; consider their relevance 
to key groups (e.g., healthcare providers, users, and policy-
makers).  
p15-18 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review level (e.g., incomplete retrieval of 
p16-17 
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identified research, reporting bias). Comment on the 
validity of the assumptions, such as transitivity and 
consistency. Comment on any concerns regarding network 
geometry (e.g., avoidance of certain comparisons). 
Conclusions  26 Provide a general interpretation of the results in the context 
of other evidence, and implications for future research.  
p17-18 
    
FUNDING    
Funding  27 Describe sources of funding for the systematic review and 
other support (e.g., supply of data); role of funders for the 
systematic review. This should also include information 
regarding whether funding has been received from 
manufacturers of treatments in the network and/or whether 
some of the authors are content experts with professional 
conflicts of interest that could affect use of treatments in 
the network. 
p1 
 
PICOS = population, intervention, comparators, outcomes, study design. 
* Text in italics indicateS wording specific to reporting of network meta-analyses that has been added 
to guidance from the PRISMA statement. 
† Authors may wish to plan for use of appendices to present all relevant information in full detail for 
items in this section. 
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Network 1
DCV PR 12 PlaceboDCV PR 16
(s) n= 1
(p) n= 26
(s) n= 2
(p) n= 104
(s) n= 1
(p) n= 27
SOF VEL(25) 12 SOF VEL(25) RBV
12(s) n= 2 
(p) n= 79 
(s) n= 1
(p) n= 53
SOF VEL 12SOF RBV 24SOF RBV 12PR 24TPR 2 PR 22 SOF VEL RBV 12
(s) n= 1
(p) n= 8
(s) n= 3
(p) n= 212
(s) n= 6
(p) n= 404
(s) n= 7
(p) n= 868
(s) n= 4 
(p) n= 371
(s) n= 2
(p) n= 65
SOF VEL 24SOF PR 12SOF 12TPR PR 24 SOF RBV 16
                   
(s) n= 1(s) n= 3 (s) n= 3(s) n= 1(s) n= 1
N t k 2 N t k 3
   
(p) n= 12
   
(p) n= 224
   
(p) n= 273
   
(p) n= 7
   
(p) n= 9
SOF LDV 12SOF LDV RBV 12 OBV PTV 12 OBV PTV RBV 12e wor e wor
(s) n= 1
(p) n= 10
(s) n= 1
(p) n= 11
(s) n= 2
(p) n= 136
(s) n= 2
(p) n= 32
Legend
SOF DCV RBV 12 SOF DCV 12SOF DCV RBV 16
(s) n= 5
(p) n= 198
(s) n= 5
(p) n= 166
(s) n= 1
(p) n= 26
Connecting lines Box lines
represents 1 study < 200 patients
200‐400 patients
represents 2 studies 400‐600 patients
3 di 600 i
SOF DCV 24SOF DCV RBV 24
(s) n= 3
(p) n= 25
(s) n= 3
(p) n= 56
represents  stu es  >   pat ents
(s) : studies subset of regimens selected
(p) : patients for ranking
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Supplementary files NMA G3  
 
Supplementary file 1. Search strategy 
We searched 3 databases (Pubmed, Embase, Web of Science) to identify all studies conducted in HCV genotype 3 patients. The search strategy included the 
following terms or synonyms: (chronic) hepatitis C, genotype 3, clinical trial (cochrane sensitivity-maximizing search), and pragmatic trial. The year 2004 was 
set as a limitation because there is no data about DAAs prior to 2004. 
We performed the first search on 7 December 2015 and repeated the search on 15 March 2016. Search strategy with items found per date are shown 
below. 
 
Pubmed 
 
 
Query 7-12-2015 
15-3-
2016 
#4 Search ((((((((((randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR drug 
therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab] NOT (animals[mh] NOT humans[mh]))))))) OR ((pragmatic 
trial[tiab]) OR pragmatic trial)) AND (((((((HCV-2/3) OR ((((G3[tiab] OR GT3[tiab] OR Genotype 3*[tiab] OR genotypes 3*[tiab] 
OR Genotype 2/3*[tiab] OR Genotypes 2/3*[tiab]))) AND (("Hepatitis C, Chronic"[Mesh] OR Hepatitis c[tiab] OR 
HCV[tiab]))))))))) Sort by: Relevance 
741 20 
#3 Search ((((((HCV-2/3) OR ((((G3[tiab] OR GT3[tiab] OR Genotype 3*[tiab] OR genotypes 3*[tiab] OR Genotype 2/3*[tiab] OR 
Genotypes 2/3*[tiab]))) AND (("Hepatitis C, Chronic"[Mesh] OR Hepatitis c[tiab] OR HCV[tiab])))))))) Sort by: Relevance 
1357 71 
#2 Search (pragmatic trial[tiab]) OR pragmatic trial Sort by: Relevance 2691 200 
#1 Search (((((((randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR drug 
therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab] NOT (animals[mh] NOT humans[mh]))))) Sort by: Relevance 
1715077 61868 
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Web of Science 
Search Items found      
7-12-2015 
Items found  
15-3-2016 
Query 
# 5 1,705  272  #3 AND #2 AND #1  
Refined by: PUBLICATION YEARS: ( 2015 OR 2006 OR 2014 OR 2009 OR 2012 OR 2008 OR 2013 OR 2005 OR 2011 OR 
2004 OR 2010 OR 2007 )  
Indexes=SCI-EXPANDED, SSCI, A&HCI, ESCI Timespan=All years 
# 4 2,262  2,262  #3 AND #2 AND #1  
Indexes=SCI-EXPANDED, SSCI, A&HCI, ESCI Timespan=All years 
# 3 292,820  292,820  TOPIC: (((((((hepatitis c) OR (chronic hepatitis c) OR HCV OR (hepatitis C virus) OR (Hep* C) OR (hepatitis NEAR C)))))))  
Indexes=SCI-EXPANDED, SSCI, A&HCI, ESCI Timespan=All years 
# 2 2,996,678  2,996,678  TOPIC: (((((((clinical trial) OR (randomi?ed clinical trial) OR (randomi?ed controlled trial) OR (clinical study) OR (clinical 
research) OR (controlled clinical trial) OR placebo OR random* OR randomi?ed OR (clinical NEAR/3 trial) OR trial OR 
(pragmatic trial) OR (pragmatic clinical trial) OR (real world) OR (real life) OR (multicent* study) OR RCT))))))  
Indexes=SCI-EXPANDED, SSCI, A&HCI, ESCI Timespan=All years 
# 1 187,811  187,811  TOPIC: (((genotypes NEAR/3 3) OR (genotype NEAR/3 3) OR G3 OR GT3 OR (GT NEAR/3 3) OR (G NEAR/3 3) OR (HCV 
NEAR/3 3)))  
Indexes=SCI-EXPANDED, SSCI, A&HCI, ESCI Timespan=All years 
 
Embase search (both searches combined) on 15-3-2016 
# ▲ Searches Results 
1 exp chronic hepatitis/ 29091  
2 (hepatitis adj C).ti,ab,kw. 87682  
3 hep* c.ti,ab,kw. 88266  
4 Hepatitis c virus.ti,ab,kw. 55326  
5 hcv.ti,ab,kw. 73000  
6 1 or 2 or 3 or 4 or 5 126732  
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7 genotypes 3.af. 292  
8 "genotype 2/3".af. 495  
9 genotype 3.af. 3078  
10 "genotypes 2/3".af. 217  
11 gt3.af. 456  
12 g3.af. 20533  
13 g?3.af. 41614  
14 7 or 8 or 9 or 10 or 11 or 12 or 13 45286  
15 "hcv-2/3".af. 52  
16 "hcv 2/3".af. 52  
17 "hcv2/3".af. 7  
18 "hcv 3".af. 281  
19 "hcv-3".af. 281  
20 "hcv3".af. 8  
21 exp hepatitis c virus genotype 3/ 575  
22 15 or 16 or 17 or 18 or 19 or 20 or 21 867  
23 6 and 14 3431  
24 22 or 23 3749  
25 Clinical trial/ 863634  
26 Randomized controlled trial/ 409625  
27 Randomization/ 70908  
28 Single blind procedure/ 22311  
29 Double blind procedure/ 131694  
30 Crossover procedure/ 47521  
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31 Crossover procedure/ 47521  
32 Randomi?ed controlled trial$.tw. 138191  
33 Rct.tw. 20739  
34 Placebo/ 289574  
35 Random allocation.tw. 1576  
36 Randomly allocated.tw. 25282  
37 Allocated randomly.tw. 2147  
38 (allocated adj2 random).tw. 839  
39 Single blind$.tw. 17802  
40 Double blind$.tw. 169626  
41 ((treble or triple) adj blind$).tw. 589  
42 Placebo$.tw. 240175  
43 Prospective study/ 338633  
44 pragmatic.tw. 13321  
45 "pragmatic clinical trial".tw. 92  
46 "real world".tw,ti,ab,kw. 28781  
47 "real life".tw,ti,ab,kw. 16689  
48 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 1652489 
49 Case study/ 38811  
50 Case report.tw. 317843  
51 letter/ 892418  
52 49 or 50 or 51 1242044 
53 48 not 52 1612479 
54 24 and 53 702  
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Supplementary file 2. Model 
This supplementary file shows the Winbugs code, the following components are shown: 
- the full model  
- the code for probability on SVR for regime 1 and 2 as an example 
- OR for ribavirin in patients with and without cirrhosis 
- Difference between 2 regimes (for example regime 1 with and without ribavirin in non-cirrhotics, for example regime 1 and 2 in cirrhotics) 
Model for Winbugs 
{ 
 for (s in 1 : 27){ 
 study_effects[s] ~ dnorm(0, study_tau) 
 } 
 for (i in 1 : 11){ 
  for (t in 1: N_study_per_regime[i]){ 
   LP[i,t] <- a1 + a2*reg_dum2[i] + a3*reg_dum3[i] + a4*reg_dum4[i] + a5*reg_dum5[i] + a6*reg_dum6[i] + a7*reg_dum7[i] + a8*reg_dum8[i] + 
a9*reg_dum9[i] + a10*reg_dum10[i] + a11*reg_dum11[i] + b1*dur_16[i,t] + b2*dur_24[i,t] + c*rbv[i,t] + d*cirr[i,t] + e*rbv[i,t]*cirr[i,t] + 
study_effects[studies[i,t]] 
   P[i,t] <- 1/ (1+exp(-1*LP[i,t])) 
   succes[i,t] ~ dbin(P[i,t], N_total[i,t]) 
  } 
 } 
a1 ~ dnorm(0, 0.01)  
a2 ~ dnorm(0, 0.01) 
a3 ~ dnorm(0, 0.01) 
a4 ~ dnorm(0, 0.01) 
a5 ~ dnorm(0, 0.01) 
a6 ~ dnorm(0, 0.01) 
a7 ~ dnorm(0, 0.01) 
a8 ~ dnorm(0, 0.01) 
a9 ~ dnorm(0, 0.01) 
a10 ~ dnorm(0, 0.01) 
a11 ~ dnorm(0, 0.01) 
b1 ~ dnorm(0, 0.01) 
b2 ~ dnorm(0, 0.01) 
c ~ dnorm(0, 0.01) 
d ~ dnorm(0, 0.01) 
e ~ dnorm(0, 0.01) 
study_sd ~ dunif(0.01, 10) 
study_tau <- 1/(study_sd*study_sd) 
P1_12_WR <- 1/(1+exp(-1*a1)) 
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P2_12_WR <- 1/(1+exp(-1*(a1+a2))) 
P1_16_WR <- 1/(1+exp(-1*(a1+b1))) 
P2_16_WR <- 1/(1+exp(-1*(a1+a2+b1))) 
P1_12_RBV <- 1/(1+exp(-1*(a1+c))) 
P2_12_RBV <- 1/(1+exp(-1*(a1+a2+c))) 
P1_16_RBV <- 1/(1+exp(-1*(a1+c+b1))) 
P2_16_RBV <- 1/(1+exp(-1*(a1+a2+c+b1))) 
P1_24_WR <- 1/(1+exp(-1*(a1+b2))) 
P2_24_WR <- 1/(1+exp(-1*(a1+a2+b2))) 
P1_24_RBV <- 1/(1+exp(-1*(a1+c+b2))) 
P2_24_RBV <- 1/(1+exp(-1*(a1+a2+c+b2))) 
P1_12_WRC <- 1/(1+exp(-1*(a1+d))) 
P2_12_WRC <- 1/(1+exp(-1*(a1+a2+d))) 
P1_16_WRC <- 1/(1+exp(-1*(a1+b1+d))) 
P2_16_WRC <- 1/(1+exp(-1*(a1+a2+b1+d))) 
P1_12_RBVC <- 1/(1+exp(-1*(a1+c+d))) 
P2_12_RBVC <- 1/(1+exp(-1*(a1+a2+c+d))) 
P1_16_RBVC <- 1/(1+exp(-1*(a1+c+b1+d))) 
P2_16_RBVC <- 1/(1+exp(-1*(a1+a2+c+b1+d))) 
P1_24_WRC <- 1/(1+exp(-1*(a1+b2+d))) 
P2_24_WRC <- 1/(1+exp(-1*(a1+a2+b2+d))) 
P1_24_RBVC <- 1/(1+exp(-1*(a1+c+b2+d))) 
P2_24_RBVC <- 1/(1+exp(-1*(a1+a2+c+b2+d))) 
 
OR_rbv <- exp(c) 
OR_rbvcirr <- exp(c+e) 
 
ZC1 <- P1_12_RBV – P1_12_WR 
C1 <- P1_24_WRC – P2_24_RBVC 
 
} 
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Supplementary file 3. Extensive baseline characteristics of included studies 
Author Acronym 
/NCT  
number 
Year Loca 
tion 
Population and 
design 
Intervention  Dura
tion 
in 
wee
ks 
N Cirrho
sis - 
n (%) 
Age, y – 
mean 
(range) 
Male sex 
– n (%) 
TN – n 
(%) 
SVR - 
n (%)
 
No SVR due to 
no EOT 
response/rela
pse/missing∞ 
Foster NCT0056
1015 
2011 EU Phase IIa RCT, TN 
G2-3 pts  
1. Placebo/PR 2 + PR 22 
2. TPR 2 + PR 24 
3. TPR/PR 2 + PR 22 
24 
26 
24 
9 
8 
9 
1 (4) 
0 
0 
39 (20-63)* 
43 (31-60)* 
44 (27-51)* 
9 (100) 
5 (63) 
8 (89) 
9 (100) 
8 (100) 
9 (100) 
4 (44) 
4 (50) 
6 (67) 
0/2/3 
2/2/0 
0/3/0 
Lawitz FISSION 2013 NA, 
EU, 
ANZ 
Phase III RCT, TN 
G2-3 pts 
1. PR (incl RBV 800 mg) 
2. SOF + RBV (wb) 
24 
12 
176 
183 
NR for 
G3 
NR for G3 NR for G3 176(100) 
183(100) 
110 (63) 
102 (56) 
NR for G3 
Jacobso
n 
POSITRO
N 
2013 NA, 
ANZ 
Phase III RCT, TN 
G2-3 pts in which 
interferon was 
not an option 
1. Placebo 
2. SOF + RBV (wb) 
12 
12 
37 
98 
0 
14 (14) 
NR for G3 NR for G3 37 (100) 
98 (100) 
0 
60 (61) 
NR for G3 
Jacobso
n  
FUSION 2013 NA, 
ANZ 
Phase III RCT, TE 
G2-3 pts 
1. SOF + RBV (wb) 
2. SOF + RBV (wb) 
12 
16 
64 
63 
26 (41) 
23 (37) 
NR for G3 NR for G3 0  
0  
19 (30) 
39 (62) 
NR for G3 
Gane ELECTRO
N 
2013 ANZ Phase IIa RCT, TN 
G2-3 pts 
1. SOF + RBV (wb) 
2. SOF/PR 4 + SOF + RBV (wb) 8  
3. SOF/PR 8 + SOF + RBV (wb) 4 
4. SOF + PR (RBV wb) 
5. SOF  
6. SOF + PR (RBV wb) 
12 
12 
12 
12 
12 
8 
6 
6 
6 
7 
7 
10 
0 
0 
0 
0 
0 
0 
NR for G3 NR for G3 6 (100) 
6 (100) 
6 (100) 
7 (100) 
7 (100) 
10 (100) 
6 (100) 
6 (100) 
6 (100) 
6 (100) 
5 (71) 
10 
(100)∫ 
0/0/0 
0/0/0 
0/0/0 
0/0/0 
0/2/0 
0/0/0 
Zeuzem  VALENCE 2014 EU Phase III RCT, 
later unblinded 
during study, TN 
and TE G2-3 pts 
1. Placebo  
2. SOF + RBV (wb) 
3. SOF + RBV (wb) 
12 
12 
24 
67 
11 
250 
0 
0 
60 (24) 
NR for G3 
46 (30-59) 
48 (19-69) 
NR for G3 
6 (55) 
155 (62) 
NR for G3 
2 (18) 
105 (42) 
0 
3 (27) 
213 (85) 
n/a 
0/6/2 
1/34/2 
Sulkows
ki 
PHOTON
-1 
2014 NA Phase III single 
arm study with 
TN and TE 
HCV/HIV 
coinfected G1-3 
pts 
1. SOF + RBV (wb)   
2. SOF + RBV (wb)  
12 
24 
42 
17 
6 (14) 
6 (35) 
<50y: 23 
< 50y: 3  
34 (81) 
14 (82) 
42 (100) 
0  
28 (67) 
16 (94) 
0/12/2 
0/1/0 
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Sulkows
ki 
AI44404
0 
2014 NA RCT, TN G1-3 pts 1. SOF 1 + SOF/DCV 23  
2. SOF + DCV  
3. SOF + DCV + RBV(800mg)  
24 
24 
24 
7 
6 
5 
0   
0   
0   
NR for G3 
 
NR for G3 
 
7 (100) 
6 (100) 
5 (100) 
5 (71) 
6 (100) 
5 (100) 
1/1/0 
0/0/0 
0/0/0 
Foster ASTRAL-
3 
2015 NA, 
EU, 
ANZ 
Phase III RCT, TN 
and TE G3 pts 
1. SOF + RBV (wb) 
2. SOF + VEL  
24 
12 
275 
277 
83 (30) 
80 (28) 
50 (19-74) 
49 (21-76) 
174 (63) 
170 (61) 
204 (74) 
206 (74) 
221 (80) 
264 (95) 
10/38/6 
0/11/2 
Foster BOSON 2015 NA, 
EU, 
ANZ 
Phase III RCT, TN 
and TE G2-3 pts 
1. SOF + PR (RBV wb) 
2. SOF + RBV (wb) 
3. SOF + RBV (wb) 
12 
16 
24 
181 
181 
182 
58 (32) 
57 (31) 
56 (31) 
<65y: 172 
<65y: 176 
<65y: 179 
121 (67) 
124 (69) 
118 (65) 
94 (52) 
91 (50) 
94 (52) 
168 (93) 
128 (71) 
153 (84) 
0/9/4 
0/50/3 
3/24/2 
Pianko NCT0190
9804 
2015 NA, 
ANZ 
Phase II RCT, TE 
G1 and 3 pts 
Non-cirrhotic pts 
1. SOF + VEL (25mg)  
2. SOF + VEL (25mg) + RBV (wb) 
3. SOF + VEL (100mg)  
4. SOF + VEL (100mg) + RBV 
(wb) 
Cirrhotic pts 
5. SOF + VEL (25mg)  
6. SOF + VEL (25mg) + RBV (wb) 
7. SOF + VEL (100mg)  
8. SOF + VEL (100mg) + RBV 
(wb) 
 
12 
12 
12 
12 
 
12 
12 
12 
12 
 
26 
28 
27 
26 
 
26 
25 
26 
26 
 
0 
0 
0 
0 
 
26 
(100) 
25 
(100) 
26 
(100) 
26 
(100) 
 
54 (22-69) 
51 (25-67) 
55 (32-68) 
56 (42-72) 
 
57 (40-68) 
56 (38-65) 
56 (45-68) 
54 (44-65) 
 
18 (69) 
22 (79) 
18 (67) 
17 (65) 
 
21 (81) 
15 (60) 
20 (77) 
20 (77) 
 
0 
0 
0 
0 
 
0 
0 
0 
0 
 
22 (85) 
27 (96) 
27 (100) 
26 (100) 
 
15 (58) 
21 (84) 
23 (88) 
25 (96) 
 
0/4/0 
0/1/0 
0/0/0 
0/0/0 
 
0/11/0 
1/3/0 
0/3/0 
0/1/0 
Nelson ALLY-3 2015 NA Phase III single 
arm study, TN 
and TE G3 pts 
1. SOF + DCV 12 152 32 (21) 55 (24-73)* 90 (59) 101 (66) 135 (89) 1/16/0 
Molina  PHOTON
-2 
2015 EU, 
ANZ 
Phase III single 
arm study, TN 
and TE HCV/HIV 
co-infected G1-4 
pts 
1. SOF + RBV (wb) 24 106 26 (25) <50y: 67 76 (72) 57 (54) 94 (89) 1/10/1 
Gane NCT0182
6981 
2015 ANZ Phase II RCT (TN) 
and single arm 
(TE) study in pts 
with G3 or G6 
1. SOF + LDV  
2. SOF + LDV + RBV (wb) 
3. SOF + LDV + RBV (wb) 
12 
12 
12 
25 
26 
50 
4 (16) 
6 (23) 
22 (44) 
43 (SD 10.2) 
48 (SD 9.2) 
52 (SD 8.2) 
13 (52) 
11 (42) 
39 (78) 
25 (100) 
26 (100) 
0 
16 (64) 
26 (100) 
41 (82) 
1/8/0 
0/0/0 
1/8/0 
Dore AI44403 2015 NA, Phase IIb RCT, TN 1. DCV + PR (RBV 800 mg) 12 26 7 (27) 46 (28-61)* 19 (73) 26 (100) 18 (69) 0/7/1 
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1 EU, 
ANZ 
G2-3 pts 2. DCV + PR (RBV 800 mg) 
3. PR + placebo (RBV 800 mg) 
16 
24 
27 
27 
4 (15) 
7 (26) 
44 (31-67)* 
46 (20-62)* 
22 (82) 
16 (59) 
27 (100) 
27 (100) 
21 (78) 
14 (52) 
0/7/1 
1/3/6 
Everson NCT0185
8766 
2015 NA Phase II RCT, TN 
G1-6 pts 
1. SOF + VEL (25mg) 
2. SOF + VEL (100 mg) 
12 
12 
27 
27 
0 
0 
52 (25-70) 
50 (20-70) 
18 (67) 
17 (63) 
27 (100) 
27 (100) 
25 (93) 
25 (93) 
1/1/0 
0/2/0 
Curry ASTRAL-
4 
2015 NA Phase III RCT, TN 
and TE G1-6 pts 
with 
decompensated 
cirrhosis 
1. SOF + VEL  
2. SOF + VEL  
3. SOF + VEL + RBV (wb) 
12 
24 
12 
14 
12 
13 
14 
(100) 
12 
(100) 
13 
(100) 
NR for G3 
 
NR for G3 
 
NR for G3 
 
7 (50) 
6 (50) 
11 (85) 
0/6/1 
1/4/1 
1/1/0 
Lawitz NR 2015 NA Phase II single 
arm study, TE G2-
3 pts 
1. SOF + PR (RBV wb) 12 24 12 (50) 54 (39-64) 18 (75) 24 (100) 20 (83) 0/2/2 
Lawitz NCT0145
8535 
2015 NA Phase II trial with 
sequential 
enrollment, TN 
G1-3 pts 
1. OMB + ABT-450 
2. OMB + ABT-450 + RBV (wb) 
12 
12 
11 
10 
0 
0 
49 (SD 8.9) 
40 (SD 13.1) 
7 (64) 
7 (70) 
11 (100) 
10 (100) 
1 (10) 
5 (50) 
9/1/0 
3/2/1 
Lin NR 2015 NR Single arm study, 
G2-3 pts, 
decompensated 
cirrhosis was 
included 
1. SOF + RBV (dose NR) 24 8 NR † NR NR NR 6 (75) ?/?/? 
Welzel CUP 2015 EU Observational 
cohort 
(compassionate 
use program), G3 
pts both HCV and 
HCV/HIV 
coinfected, 
decompensated 
cirrhosis was 
included 
1. SOF + DCV 
2. SOF + DCV 
3. SOF + DCV + RBV (dose NR)  
4. SOF + DCV + RBV (dose NR) 
12 
24 
12 
24 
3 
8 
3 
7 
3 (100) 
8 (100) 
3 (100) 
7 (100) 
NR NR NR 3 (100) 
8 (100) 
3 (100) 
6 (86) 
0/0/0 
0/0/0 
0/0/0 
?/1/? 
Hezode ATU 2015 EU 
(Fran
ce) 
Observational 
cohort 
(compassionate 
use program), TN 
1. SOF + DCV 
2. SOF + DCV 
3. SOF + DCV + RBV (dose NR) 
4. SOF + DCV + RBV (dose NR) 
12 
24 
12 
24 
26 
35 
4 
13 
22 (85) 
35 
(100) 
3 (75) 
NR NR NR 22 (85) 
32 (91) 
4 (100) 
12 (92) 
No VB, 6 
relapse, 6 
unknown 
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and TE G3 pts 
both HCV and 
HCV/HIV 
coinfected, 
decompensated 
cirrhosis was 
included 
13 
(100) 
Poordad ALLY-1 2015 NA Single arm study, 
TN and TE G1-6 
pts with 
advanced fibrosis 
or post-liver 
transplant HCV 
recurrence 
1. Advanced cirrhosis cohort : 
SOF + DCV + RBV (600 mg) 
2. Posttransplant cohort: 
 SOF + DCV + RBV (600 mg) 
12 
 
 
12 
6 
 
 
11 
6 (100) 
 
 
NR † 
NR NR NR 5 (83) 
 
 
10 (91) 
?/?/? 
 
?/?/? 
Wyles ALLY-2 2015 NA Phase II RCT (TN) 
and single arm 
(TE), G1-4 
HCV/HIV 
coinfected pts 
1. SOF + DCV  
2. SOF + DCV  
3. SOF + DCV  
8 
12 
12 
3 
6 
4 
1 (33) 
0 
1 (25) 
NR for G3 
 
NR for G3 
 
3 (100) 
6 (100) 
0 
2 (67) ∫ 
6 (100) 
4 (100) 
0/1/0 
0/0/0 
0/0/0 
Foster EAP 2016 EU Observational 
cohort 
(expanded access 
programme), G1-
6 TN and TE, 
both HCV and 
HCV/HIV 
coinfected 
patients, 
decompensated 
cirrhosis was 
included 
1. SOF + DCV 
2. SOF + DCV + RBV (dose NR) 
3. SOF + LDV 
4. SOF + LDV + RBV (dose NR) 
12 
12 
12 
12 
7 
118 
7 
60 
5 (71) 
115 
(97) 
7 (100) 
59 (98) 
‡ 
(arm1+2): 
52* 
(arm3+4): 
54* 
(arm1+2): 
90 (72) 
(arm3+4): 
44 (66) 
(arm1+2): 
49 (39) 
(arm3+4): 
30 (45) 
 
5 (71) 
86 (73) 
2 (29) 
39 (65) 
(arm1+2): 
0/18/16 
(arm3+4): 
1/20/5 
Shah NR 2016 Asia 
(India
) 
RCT, TN G1 and 
G3 pts 
1. SOF + RBV (wb) 
2. SOF + RBV (wb) 
16 
24 
29 
30 
7 (24) 
7 (23) 
NR NR 29 (100) 
30 (100) 
29 (100) 
28 (93) 
0/0/0 
0/1/1 
Leroy ALLY-3+ 2016 EU, 
ANZ 
Phase IIIb RCT, 
TN and TE G3 pts 
1. SOF + DCV + RBV (wb) 
2. SOF + DCV + RBV (wb) 
12 
16 
24 
26 
18 (75) 
18 (69) 
53 (36-73)* 
56 (42-62)* 
18 (75) 
22 (85) 
6 (25) 
7 (27) 
21 (88) 
24 (92) 
0/2/1 
0/2/0 
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NR = Not Reported, EU = Europe, NA= North America, ANZ = Australia and New-Zealand, TN = treatment naive, TE = treatment experienced, HCV= hepatitis C virus, HIV = 
human immunodeficiency virus, RCT = randomized clinical trial, NR = not reported, G=genotype, pts = patients, y = years. 
Interventions: TEL = telaprevir, IFN = peginterferon, RBV = ribavirin (dose: xxx mg or wb = weight based dose of RBV: 1000 mg daily if body weight < 75 kg, and 1200 mg 
daily if body weight ≥ 75 kg), SOF = sofosbuvir, DCV = daclatasvir, VEL = velpatasvir, LDV = ledipasvir, OMB = ombitasvir, AB -450 = paritaprevir, PR = Peginterferon and RBV. 
†All paLents counted as cirrhosis. 
‡ Patients with decompensated liver disease and orthoptic liver transplant were counted as cirrhosis, while patients with extrahepatic indication were counted as non-
cirrhosis 
∫ The treatment arms with 8 weeks duration are not included in the analysis 
* median (range) 
∞ Reasons for no end of treatment (EOT) response include: viral breakthrough (VB), non-response, early discontinuation; Reasons for missing include: lost to follow-up, 
withdrew consent, died  
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Supplementary file 4 
a) Patients without cirrhosis 
• Subset of regimens recommended in guidelines (EASL, AALSD, WHO) or under evaluation of regulatory authorities:  
Italic regimens are recommended in latest update of AASLD guideline (6 July 2016) 
i. SOF + DCV 12   
ii. SOF + PR 12   
iii. SOF + RBV 24 
iv. SOF + DCV + RBV 12  
v. SOF + VEL 12 
vi. SOF + VEL + RBV 12 
• Rankograms for subset of regimens patients without cirrhosis: 
1.   2.  3.  
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4.   5.   6.  
 
 
 
 
b) Patients with cirrhosis 
• Subset of regimens recommended in guidelines (EASL, AALSD, WHO) or under evaluation of regulatory authorities: 
Italic regimens are recommended in latest update of AASLD guideline (6 July 2016) 
i. SOF + DCV + RBV 24 
ii. SOF + DCV 24   
iii. SOF + PR 12   
iv. SOF + RBV 24 
v. SOF + DCV + RBV 12  
vi. SOF + VEL 24 
vii. SOF + VEL + RBV 12 
viii. SOF + VEL 12 
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• Rankograms for subset of regimens in cirrhotic patients: 
1.   2.   3.  
4.   5.   6.  
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7.  8.  
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Supplementary file 5.  
Meta-analyses per studied regimen in patients without cirrhosis (only regimens with >1 study are shown). 
SOF RBV 12 
 
SOF RBV 16 
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SOF RBV 24 
 
PR 24 
 
Placebo 
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SOF DCV 12 
 
SOF DCV RBV 12 
 
SOF LDV RBV 12 
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SOF PR 12 
 
SOF VEL(25mg) 12 
 
SOF VEL(100mg) 12 
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Meta-analyses per studied regimen in patients with cirrhosis (only regimens with >1 study are shown). 
SOF RBV 12 
 
SOF RBV 16 
 
SOF RBV 24 
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SOF DCV 12 
 
SOF DCV RBV 12 
 
SOF DCV RBV 24 
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SOF LDV 12 
  
SOF LDV RBV 12 
 
SOF PR 12 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
SOF VEL(100mg) 12 
 
 
SOF VEL(100mg) RBV 12 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Supplementary file 6. 
Excluded studies in sensitivity analyses: 
a) Excluding high risk of bias studies: Foster (EAP), Gane (ELECTRON), Hézode (ATU), Lawitz (FISSION), Lawitz 2015, Lawitz 2015, Lin 2015, Molina (PHOTON-
2), Nelson (ALLY-3), Poordad (ALLY-1), Shah 2016, Sulkowski (PHOTON-1), Welzel (CUP), Wyles (ALLY-2), Zeuzem (VALENCE) 
b) Excluding studies with not approved regimens: Foster 2011, Dore (AI444-031), Lawitz 2015, Pianko (2015), Everson (2015) 
c) Excluding studies with decompensated liver disease patients: Curry (ASTRAL-4), Foster (EAP), Lin 2015, Welzel (CUP), Hézode (ATU), Poordad (ALLY-1) 
d) Excluding studies with HIV/HCV coinfected patients: Sulkowski (PHOTON-1), Molina (PHOTON-2), Wyles (ALLY-2), Welzel (CUP), Hézode (ATU), Foster 
(EAP) 
 
Sensitivity analyses patients without cirrhosis 
Regimen  Primary analysis 
including all 
studies 
a) Analysis 
excluding 
high risk of 
bias studies 
b) Analysis 
excluding not 
approved 
regimens 
c) Analysis excluding 
studies with 
decompensated 
liver disease 
patients 
d) Analysis excluding 
studies with 
HIV/HCV 
coinfected 
patients 
SOF + DCV + RBV 24 98.9 (97.6-99.6) 96.8 (88.2-99.6) 98.9 (97.5-99.7) 99.3 (98.1-99.8) 98.8 (96.4-99.8) 
SOF + VEL(100mg) + RBV 12 98.8 (97.5-99.6) 98.8 (97.0-99.7) 98.8 (96.9-99.7) 99.4 (98.7-99.8) 99.3 (98.2-99.8) 
SOF + DCV + RBV 16 98.0 (95.7-99.2) 94.7 (80.8-99.4) 98.1 (95.7-99.4) 98.4 (95.9-99.6) 97.7 (93.4-99.5) 
SOF + DCV 24 97.3 (94.2-99.0) 88.6 (63.0-98.5) 97.7 (94.6-99.3) 97.8 (94.2-99.4) 95.7 (87.4-99.1) 
SOF + VEL(100mg) 12 97.2 (94.7-98.8) 95.3 (89.4-98.5) 97.5 (94.7-99.1) 98.3 (96.6-99.3) 97.4 (94.6-99.0) 
SOF + DCV + RBV 12 95.6 (91.6-98.1) 91.0 (68.9-98.8) 95.3 (90.5-98.2) 95.9 (89.9-98.8) 95.0 (86.2-98.8) 
SOF + PR 12 95.0 (90.6-97.8) 91.7 (80.8-97.3) 95.4 (90.9-98.1) 95.7 (92.1-98.1) 94.6 (89.3-97.9) 
SOF + VEL(25mg) + RBV 12 94.3 (86.6-98.3) 94.7 (85.7-98.7) Excluded 96.4 (91.3-99.1) 96.0 (89.5-99.0) 
SOF + LDV + RBV 12 92.6 (84.9-97.2) 88.5 (55.9-99.0) 92.1 (83.2-97.4) 89.2 (67.5-98.3) 88.1 (54.7-99.0) 
SOF + DCV 12 89.9 (80.9-95.6) 73.3 (33.1-95.2) 90.5 (80.4-96.3) 88.3 (73.5-96.1) 84.3 (61.8-95.7) 
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SOF + VEL(25mg) 12 87.4 (73.8-95.5) 82.0 (60.7-94.1) Excluded 89.9 (79.2-96.5) 87.3 (72.2-96.0) 
SOF + RBV 24 87.3 (80.5-92.4) 79.3 (62.1-90.8) 87.9 (80.3-93.5) 90.3 (85.2-94.4) 86.5 (77.6-93.1) 
SOF + LDV 12 83.8 (68.7-93.5) 69.3 (22.1-95.9) 84.9 (68.6-94.6) 74.0 (36.6-94.5) 71.0 (23.7-96.5) 
DCV + PR 16 81.2 (61.5-93.4) 71.5 (32.6-94.0) Excluded 82.3 (64.1-93.6) 80.3 (58.7-93.6) 
SOF + RBV 16 78.8 (67.8-87.3) 68.9 (46.6-85.2) 80.8 (69.2-89.7) 80.8 (71.4-88.4) 77.4 (63.9-87.7) 
TPR + PR 24 70.2 (37.6-92.4) 64.5 (24.4-93.2) Excluded 67.9 (36.2-91.0) 70.3 (35.9-93.2) 
PR 24 67.6 (52.7-80.2) 56.4 (19.9-87.0) 67.9 (50.0-82.3) 65.9 (51.6-78.3) 65.6 (47.7-80.7) 
DCV + PR 12 66.6 (40.4-86.6) 59.8 (20.9-89.4) Excluded 63.7 (38.2-84.2) 64.7 (36.1-86.7) 
SOF + RBV 12 62.5 (48.8-74.6) 55.4 (30.6-76.4) 61.9 (45.8-76.1) 60.8 (47.5-72.4) 60.0 (42.8-75.2) 
OMB + PTV + RBV 12 39.1 (7.1-81.6) Excluded Excluded 41.1 (9.8-81.0) 42.7 (6.1-88.0) 
SOF 12 41.1 (22.7-60.5) 24.7 (7.3-51.1) 44.3 (21.9-67.6) 33.4 (16.5-51.8) 30.2 (13.1-51.5) 
OMB + PTV 12 23.3 (2.9-63.9) Excluded  Excluded 20.4 (3.0-56.0) 20.9 (1.6-66.1) 
      
OR RBV 2.6 (1.3-4.7) 4.6 (1.9-9.3) 2.3 (1.0-4.6) 3.4 (1.6-6.6) 3.9 (1.8-7.5) 
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Sensitivity analyses patients with cirrhosis 
Regimen  Primary analysis 
including all 
studies 
a) Analysis 
excluding 
high risk of 
bias studies 
b) Analysis 
excluding not 
approved 
regimens 
c) Analysis excluding 
studies with 
decompensated 
liver disease 
patients 
d) Analysis excluding 
studies with 
HIV/HCV 
coinfected 
patients 
SOF + VEL(100mg) 24 96.3 (92.0-98.7) 93.2 (83.2-98.4) 96.7 (92.3-99.1) 98.4 (96.2-99.5) 96.2 (91.0-98.9) 
SOF + DCV + RBV 24 94.1 (86.8-98.1) 87.6 (58.7-98.7) 93.6 (84.4-98.3) 96.0 (88.8-99.2) 92.8 (79.3-98.7) 
SOF + VEL(100mg) + RBV 12 93.7 (85.9-98.0) 94.6 (85.7-98.8) 92.9 (82.0-98.4) 96.8 (92.4-99.1) 95.4 (88.8-98.8) 
SOF + DCV + RBV 16 89.8 (77.9-96.6) 81.0 (44.5-97.6) 89.6 (75.8-97.0) 91.8 (78.4-98.1) 87.7 (66.9-97.4) 
SOF + DCV 24 87.3 (75.8-94.7) 67.0 (26.8-94.0) 88.1 (75.7-95.5) 88.9 (73.3-96.9) 79.5 (52.7-94.6) 
SOF + VEL(100mg) 12 86.8 (77.4-93.6) 82.2 (66.5-93.2) 87.4 (76.7-94.8) 91.2 (84.2-96.1) 86.2 (75.1-94.1) 
SOF + DCV + RBV 12 80.1 (62.7-92.0) 71.7 (29.8-95.7) 77.4 (56.1-91.9) 81.0 (57.9-94.6) 76.5 (47.7-93.9) 
SOF + PR 12 77.8 (59.6-90.5) 71.6 (43.8-90.8) 77.8 (57.4-91.5) 79.7 (62.1-91.8) 74.5 (52.7-89.9) 
SOF + VEL(25mg) + RBV 12 75.8 (50.4-92.5) 80.2 (52.8-95.3) Excluded 83.1 (61.9-95.6) 80.1 (54.9-94.9) 
SOF + LDV + RBV 12 70.3 (47.0-88.3) 67.7 (20.0-96.3) 67.4 (41.0-88.1) 63.3 (24.8-91.8) 61.5 (15.5-94.8) 
SOF + DCV 12 63.3 (44.5-79.5) 43.0 (9.6-82.5) 63.2 (42.0-80.9) 59.4 (31.9-82.1) 50.1 (20.6-78.8) 
SOF + VEL(25mg) 12 58.0 (34.1-79.6) 52.5 (25.6-78.2) Excluded 62.9 (39.1-83.5) 55.3 (29.3-79.6) 
SOF + RBV 24 56.3 (37.6-73.8) 47.3 (22.7-73.6) 55.8 (34.2-75.9) 62.7 (43.1-79.7) 52.0 (30.9-73.0) 
SOF + LDV 12 50.6 (29.3-72.1) 39.6 (5.9-84.8) 51.0 (27.9-73.9) 38.7 (9.1-76.0) 36.1 (4.7-82.2) 
DCV + PR 16 46.9 (20.5-74.9) 40.5 (8.9-80.4) Excluded 47.6 (21.3-75.4) 43.0 (16.6-73.1) 
SOF + RBV 16 41.6 (23.8-61.2) 34.7 (13.8-61.6) 43.0 (22.6-65.2) 43.8 (25.2-63.9) 37.2 (18.7-59.0) 
DCV + PR 12 29.5 (9.8-57.9) 28.9 (5.0-68.7) Excluded 26.2 (8.7-53.0) 25.9 (7.5-54.9) 
PR 24 28.9 (14.2-47.9) 25.8 (4.7-63.9) 28.0 (11.2-50.1) 26.7 (12.8-45.3) 25.1 (10.7-45.4) 
SOF + RBV 12 24.5 (12.2-40.7) 23.3 (7.5-47.7) 22.9 (9.9-41.2) 22.5 (11.0-38.3) 20.8 (8.9-38.1) 
      
OR RBV 4.5 (2.5-7.7) 6.9 (3.0-14.2) 4.4 (2.1-8.3) 6.4 (2.7-13.3) 7.8 (3.6-15.4) 
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Supplementary file 7.  
a) Risk of bias across studies         b) Risk of bias per study  
 
 
 
 
 
 
 
 
Legend. These graphs shows risk of bias on 7 components across studies (a) and per study (b). Risk of bias was 
assessed with the Cochrane risk of bias tool 
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Supplementary file 8. Analysis with treatment naïve and treatment experienced patients 
Treatment naïve patients          Treatment experienced patients 
Regimen  Estimated SVR (95% CrI)   Regimen  Estimated SVR (95% CrI)  
SOF + DCV + RBV 24 98.3 (96.2-99.5)  SOF + VEL(100mg) 24 98.1 (95.4-99.5) 
SOF + VEL(100mg) + RBV 12 98.8 (97.3-99.6)  SOF + DCV + RBV 24 96.9 (92.0-99.2) 
SOF + DCV + RBV 16 97.2 (93.4-99.1)  SOF + VEL(100mg) + RBV 12 97.8 (94.5-99.4) 
SOF + DCV 24 94.2 (86.9-98.1)  SOF + DCV + RBV 16 94.7 (86.5-98.6) 
SOF + VEL(100mg) 12 95.8 (91.6-98.3)  SOF + DCV 24 89.6 (76.5-96.7) 
SOF + DCV + RBV 12 93.1 (85.7-97.5)  SOF + VEL(100mg) 12 92.4 (84.7-97.1) 
SOF + PR 12 94.4 (88.6-97.8)  SOF + DCV + RBV 12 87.8 (72.7-96.2) 
SOF + LDV + RBV 12 88.9 (75.9-96.4)  SOF + PR 12 89.9 (77.8-96.7) 
SOF + DCV 12 78.6 (60.5-90.9)  SOF + LDV + RBV 12 81.1 (58.7-94.4) 
SOF + RBV 24 86.0 (76.5-92.7)  SOF + DCV 12 66.8 (42.5-85.6) 
SOF + LDV 12 68.8 (44.9-86.9)  SOF + RBV 24 76.6 (58.2-89.6) 
DCV + PR 16 86.8 (69.9-96.0)  SOF + LDV 12 55.2 (28.4-79.8) 
SOF + RBV 16 77.6 (63.7-88.0)  SOF + RBV 16 65.2 (43.1-83.1) 
TPR + PR 24 70.0 (34.7-93.4)  SOF + RBV 12 43.1 (22.7-65.3) 
PR 24 63.4 (45.1-79.1)  SOF + VEL(25mg) + RBV 12 90.6 (75.5-97.8) 
DCV + PR 12 72.5 (46.2-90.7)  SOF + VEL(25mg) 12 73.5 (48.4-90.5) 
SOF + RBV 12 57. (40.7-73.4)    
OMB + PTV + RBV 12 43.5 (5.4-90.2)    
SOF 12 27.4 (12.8-46.1)    
OMB + PTV 12 21.4 (1.4-70.0)    
SOF + VEL(25mg) 12 83.3 (64.7-94.4)    
 
